Literature DB >> 22615010

Growth charts for individuals with Smith-Lemli-Opitz syndrome.

Ryan W Y Lee1, John McGready, Sandra K Conley, Nicole M Yanjanin, Małgorzata J M Nowaczyk, Forbes D Porter.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a rare multiple congenital anomaly neurodevelopmental syndrome of impaired cholesterol synthesis. Growth restriction and developmental delay are very common clinical manifestations of SLOS. The degree, etiology, and consequences of growth restriction in SLOS remain an area of limited knowledge to the scientific community. There have been no studies describing the growth parameters and providing reference growth charts for individuals with SLOS. Our longitudinal data from 78 patients between the ages of 0.1 and 16 years with SLOS show a growth restriction of about two standard deviations below the Centers for Disease Control (CDC) norms for age. This study represents comprehensive anthropometric data from the largest cohort available, and proposes growth charts for widespread use in the management and study of individuals with SLOS.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22615010      PMCID: PMC3427420          DOI: 10.1002/ajmg.a.35376

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  24 in total

Review 1.  The Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; R C Hennekam
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

2.  Frequency and ethnic distribution of the common DHCR7 mutation in Smith-Lemli-Opitz syndrome.

Authors:  M J Nowaczyk; L M Nakamura; B Eng; F D Porter; J S Waye
Journal:  Am J Med Genet       Date:  2001-09-01

3.  CDC growth charts: United States.

Authors:  R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson
Journal:  Adv Data       Date:  2000-06-08

Review 4.  RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis.

Authors:  F D Porter
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

5.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

6.  Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome.

Authors:  P E Jira; R A Wevers; J de Jong; E Rubio-Gozalbo; F S Janssen-Zijlstra; A F van Heyst; R C Sengers; J A Smeitink
Journal:  J Lipid Res       Date:  2000-08       Impact factor: 5.922

7.  Weight for age charts for children with achondroplasia.

Authors:  J E Hoover-Fong; J McGready; K J Schulze; H Barnes; C I Scott
Journal:  Am J Med Genet A       Date:  2007-10-01       Impact factor: 2.802

8.  Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS).

Authors:  D Haas; S F Garbade; C Vohwinkel; N Muschol; F K Trefz; J M Penzien; J Zschocke; G F Hoffmann; P Burgard
Journal:  J Inherit Metab Dis       Date:  2007-05-11       Impact factor: 4.982

9.  Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome.

Authors:  K P Battaile; B C Battaile; L S Merkens; C L Maslen; R D Steiner
Journal:  Mol Genet Metab       Date:  2001-01       Impact factor: 4.797

10.  Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene.

Authors:  H R Waterham; F A Wijburg; R C Hennekam; P Vreken; B T Poll-The; L Dorland; M Duran; P E Jira; J A Smeitink; R A Wevers; R J Wanders
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

View more
  2 in total

1.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

2.  Growth standard charts for monitoring bodyweight in dogs of different sizes.

Authors:  Carina Salt; Penelope J Morris; Alexander J German; Derek Wilson; Elizabeth M Lund; Tim J Cole; Richard F Butterwick
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.